Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NeoFuse

Cell therapy (Stem-cell derived) · developed by Mesoblast

Phase 1/2 Most advanced trial (none active)
MESO Developer
1 Registered trials

What is NeoFuse?

NeoFuse is an adult stem cell-based implant, surgically placed in the spine.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Cervical Spinal Fusion
Drug type
Cell therapy (Stem-cell derived)
Therapy area
Musculoskeletal
Developer
Mesoblast, Ltd. (MESO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
4LS0IJZ59V

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01106417 Phase 1/2 Cervical Degenerative Disc Disease Completed MESO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cervical Degenerative Disc DiseaseDegenerative SpondylolisthesisSpinal Stenosis

More from Mesoblast

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MESO page.

Follow MESO, the company behind NeoFuse

See MESO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MESO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.